Scotland, Graham; Waugh, Norman; Royle, Pamela; … - In: PharmacoEconomics 29 (2011) 11, pp. 951-961
fracture by 40%, and reduced the incidence of clinical vertebral fracture by 69%. An indirect treatment comparison was used to … derive adjusted relative risk (RR) estimates for different types of fracture for each comparator versus placebo. The RRs (95 …% CI) applied for denosumab were 0.316 (0.208, 0.478) for clinical vertebral fracture, 0.605 (0.373, 0.983) for hip …